Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

OBIO

Orchestra BioMed Holdings Inc

May 29 • 04:00PM ET

3.91

-0.07 -1.76 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: HRTX FENC RNAC SLGL ARCT BCYC FATE FHTX VYGR CDXS

| Held by: VTI VXF SURI SCHA IWC SCHB AVSC IBBQ BIB

Index	-	P/E	-	EPS (ttm)	-1.13	Insider Own	30.57%	Shs Outstand	58.63M	Perf Week	-4.63%
Market Cap	234.13M	Forward P/E	-	EPS next Y	-1.36	Insider Trans	0.24%	Shs Float	41.58M	Perf Month	2.89%
Enterprise Value	183.13M	PEG	-	EPS next Q	-0.39	Inst Own	41.04%	Short Float	2.03%	Perf Quarter	-10.73%
Income	-54.86M	P/S	7.16	EPS this Y	-40.93%	Inst Trans	1.98%	Short Ratio	3.80	Perf Half Y	-26.92%
Sales	32.72M	P/B	5.57	EPS next Y	13.06%	ROA	-68.42%	Short Interest	0.84M	Perf YTD	-5.78%
Book/sh	0.70	P/C	2.48	EPS next 5Y	7.92%	ROE	-161.12%	52W High	5.42 -27.91%	Perf Year	38.16%
Cash/sh	1.58	P/FCF	-	EPS past 3/5Y	20.91% -164.92%	ROIC	-65.19%	52W Low	2.20 77.73%	Perf 3Y	-73.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	111.62% -	Gross Margin	98.65%	Volatility	3.46% 4.91%	Perf 5Y	-61.93%
Dividend TTM	-	EV/Sales	5.60	EPS Y/Y TTM	36.35%	Oper. Margin	-167.96%	ATR (14)	0.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.01	Sales Y/Y TTM	1033.89%	Profit Margin	-167.63%	RSI (14)	44.53	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	7.03	EPS Q/Q	32.86%	SMA20	-2.09%	Beta	0.50	Target Price	12.17
Payout	-	Debt/Eq	0.66	Sales Q/Q	-87.33%	SMA50	-6.57%	Rel Volume	0.87	Prev Close	3.98
Employees	86	LT Debt/Eq	0.64	Earnings	May 12 AMC	SMA200	0.91%	Avg Volume	221.60K	Price	3.91
IPO	Aug 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	23.34% -88.03%	Trades		Volume	192,799	Change	-1.76%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Initiated	TD Cowen	Buy	$15
Aug-20-25	Downgrade	BTIG Research	Buy → Neutral
Mar-20-25	Initiated	BTIG Research	Buy	$12
Jan-02-25	Initiated	Barclays	Overweight	$16
Aug-22-24	Initiated	H.C. Wainwright	Buy	$14
Jul-25-24	Initiated	B. Riley Securities	Buy	$15
Jan-19-24	Initiated	Jefferies	Buy	$14
Feb-24-23	Initiated	Piper Sandler	Overweight	$15
Feb-07-23	Initiated	Chardan Capital Markets	Buy	$20

May-19-26 08:30AM	Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 04:18PM	Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
08:30AM	Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 (GlobeNewswire)
May-06-26 08:01AM	Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement (GlobeNewswire)
08:00AM	Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement (GlobeNewswire)
09:00AM	Loading…
Apr-30-26 09:00AM	FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy (GlobeNewswire) +5.00%
Apr-23-26 12:00PM	Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 (GlobeNewswire)
Mar-12-26 08:17AM	Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Mar-03-26 08:00AM	Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT (GlobeNewswire)
Feb-19-26 08:00AM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire)
Feb-13-26 04:05PM	Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-12-26 09:00AM	Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics (GlobeNewswire)
Dec-31-25 11:13AM	TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs (Insider Monkey)
Dec-08-25 07:00AM	Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting (GlobeNewswire)
Nov-29-25 01:25AM	Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements (Insider Monkey)
04:05PM	Loading…
Nov-26-25 04:05PM	Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-25 09:00AM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire) +8.47%
07:31AM	What To Expect From Orchestra BioMed Holdings Inc (OBIO) Q3 2025 Earnings (GuruFocus.com)
Nov-10-25 05:30PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:10PM	Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
08:40AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.32%
Nov-03-25 08:00AM	Orchestra BioMed to Host Business Update Call on November 12, 2025 (GlobeNewswire)
Oct-28-25 08:00AM	Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements (GlobeNewswire)
Oct-27-25 09:00AM	Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial (GlobeNewswire)
Oct-09-25 08:00AM	Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit (GlobeNewswire)
Sep-04-25 05:00PM	Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout (GlobeNewswire)
Aug-26-25 07:30AM	Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology (GlobeNewswire) +15.38%
Aug-14-25 08:00AM	Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction (GlobeNewswire)
Aug-13-25 08:00AM	Campbellford Memorial Hospitals New Homecare Program Frees up 14.5 Hospital Bed-Days Per Patient Through a Partnership With Gotcare and OBIO® (Business Wire)
03:00PM	Loading…
Aug-12-25 03:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +7.94%
08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-08-25 07:00AM	Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Aug-04-25 05:55PM	CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +9.84%
Aug-01-25 07:59AM	Orchestra BioMed Announces Pricing of $40 Million Public Offering (GlobeNewswire) -20.26%
Jul-31-25 04:02PM	Orchestra BioMed Announces Proposed Public Offering (GlobeNewswire)
04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-16-25 08:00AM	OBIO® Paves the Way for Companies to Succeed in Canada as a Stepping Stone to New Global Markets (Business Wire) +7.88%
Jun-18-25 09:30AM	Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 (GlobeNewswire) -11.01%
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-12-25 05:40PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.94%
04:28PM	Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones (GlobeNewswire)
May-07-25 08:30AM	Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure (GlobeNewswire)
May-06-25 05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.47%
May-05-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -6.57%
Apr-29-25 09:00AM	Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon (GlobeNewswire)
Apr-28-25 04:30PM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire) -6.12%
Apr-23-25 09:00AM	Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting (GlobeNewswire)
Apr-22-25 07:00AM	Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy (GlobeNewswire)
Mar-31-25 07:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -24.30%
04:21PM	Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update (GlobeNewswire)
Mar-24-25 09:10AM	Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-20-25 08:00AM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire) -8.77%
Feb-18-25 08:00AM	Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board (GlobeNewswire)
Feb-12-25 10:43AM	Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference (GlobeNewswire)
Feb-05-25 08:00AM	Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors (GlobeNewswire)
Dec-09-24 07:00AM	Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting (GlobeNewswire) +9.54%
Nov-26-24 04:05PM	Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.67% +7.24%
04:12PM	Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-07-24 08:00AM	Orchestra BioMed to Participate in Jefferies London Healthcare Conference (GlobeNewswire) -5.50%
Aug-12-24 05:35PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:20PM	Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-24 09:35AM	Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +13.55%
Aug-01-24 10:01AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -7.18%
Jul-30-24 08:00AM	Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors (GlobeNewswire)
Jul-26-24 12:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know (Zacks) -6.70%
09:55AM	Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade (Zacks)
Jul-23-24 09:00AM	Precision Neuroscience Expands Executive Team as Brain Computer Interface Industry Rapidly Advances (GlobeNewswire)
Jun-24-24 08:07AM	Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar? (Zacks) +9.02%
Jun-04-24 08:00AM	Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire) +10.64%
Jun-03-24 12:00PM	All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy (Zacks)
09:55AM	Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect? (Zacks)
May-22-24 08:43AM	Orchestra BioMed to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 09:53PM	OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +13.04%
06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:58PM	Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-30-24 08:30AM	Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents (GlobeNewswire)
08:00AM	Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire)
Mar-27-24 04:17PM	Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Mar-26-24 08:00AM	Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors (GlobeNewswire) +5.20%
Mar-13-24 08:00AM	Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 08:00AM	Orchestra BioMed to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.62%
Mar-06-24 08:37AM	Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients (GlobeNewswire)
Feb-26-24 08:00AM	Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years (GlobeNewswire)
Feb-16-24 09:13AM	Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season (Zacks) -8.45%
Jan-08-24 07:30AM	Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients (GlobeNewswire) +9.38%
Nov-13-23 04:21PM	Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +14.61% +13.08%
Nov-09-23 04:42PM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-30-23 03:52PM	Billionaire Marc Lasrys Top 10 Stock Picks (Insider Monkey)
Sep-22-23 11:27AM	Lab Notes: Main Line firm spins off company that will focus on OTC product pipeline (American City Business Journals)
Sep-19-23 02:37PM	Rebel's Edge - September 19: $NIO, $BHC, $OBIO, and the Firing of MSU's Football Coach (TheStreet.com) +27.61%
07:30AM	Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients (GlobeNewswire)
Sep-06-23 05:00PM	Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors (GlobeNewswire) -7.74%
Aug-10-23 04:34PM	Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.05%
Aug-08-23 08:30AM	Orchestra BioMed Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon in Patients with Coronary In-Stent Restenosis (GlobeNewswire)
Jul-27-23 09:47AM	Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) stock most popular amongst retail investors who own 36%, while hedge funds hold 28% (Simply Wall St.) -14.00%
Jun-28-23 02:16PM	Why Shares of Orchestra BioMed Holdings Jumped Wednesday (Motley Fool) +24.85%
Jun-26-23 08:00AM	Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes (GlobeNewswire) -9.81%

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded by David P. Hochman on May 25, 2020 and is headquartered in New Hope, PA.

FounderMr. David P. Hochman

FounderMr. Darren R. Sherman

Chief Financial OfficerMr. Andrew Lawrence Taylor M.B.A.

Executive Vice President of Corporate Development & StrategyMr. William Reed Little

Vice President of Human ResourcesMs. Lisa Daniels

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aryeh Jason	Director	May 18 '26	Buy	3.75	665	2,494	118,118	May 20 08:00 AM
Aryeh Jason	Director	May 15 '26	Buy	3.90	8,971	34,987	117,453	May 19 08:00 AM
Hochman David P	See Remarks	May 15 '26	Buy	3.77	5,000	18,850	1,059,029	May 19 08:00 AM
Fain Eric S	Director	May 14 '26	Buy	4.13	20,000	82,600	91,709	May 18 08:00 AM
RTW INVESTMENTS, LP	10% Owner	Apr 27 '26	Sale	4.13	32	132	9,556,063	Apr 29 05:36 PM
Hochman David P	See Remarks	Mar 13 '26	Buy	4.29	10,000	42,900	1,086,467	Mar 16 04:54 PM
Hochman David P	See Remarks	Nov 14 '25	Buy	4.07	5,000	20,350	612,822	Nov 17 05:00 PM
Aryeh Jason	Director	Sep 19 '25	Buy	2.45	1,000	2,450	108,482	Sep 19 06:57 PM
Fain Eric S	Director	Aug 25 '25	Buy	2.61	5,760	15,034	71,709	Aug 25 07:04 PM
Sherman Darren	See Remarks	Aug 25 '25	Buy	2.62	3,000	7,860	926,837	Aug 25 07:04 PM
Hochman David P	See Remarks	Aug 21 '25	Buy	2.49	6,000	14,940	651,460	Aug 25 07:03 PM
Taylor Andrew Lawrence	Chief Financial Officer	Aug 25 '25	Buy	2.55	2,000	5,100	482,788	Aug 25 07:01 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Aug 01 '25	Buy	2.75	700,000	1,925,000	5,292,556	Aug 05 10:46 AM
Hochman David P	See Remarks	Aug 04 '25	Buy	2.75	20,000	55,000	349,331	Aug 04 06:16 PM
Fain Eric S	Director	Jun 26 '25	Sale	3.05	2,683	8,183	50,949	Jun 27 05:10 PM
Fain Eric S	Director	Jun 26 '25	Proposed Sale	3.05	2,683	8,194		Jun 26 03:11 PM

Open in Screener

LGND

Ligand Pharmaceuticals Inc

May 29 • 04:00PM ET

231.96

-2.70 -1.15 %

Healthcare • Biotechnology • USA • Mid • NASD

LGND Ligand Pharmaceuticals Inc daily Stock Chart

Peers: BMRN IONS RYTM VKTX ALNY INCY AXSM MDGL KROS NBIX

| Held by: IJR VTI IWM VB VBR VXF SPSM IJT XSMO IWN

Index	RUT	P/E	31.45	EPS (ttm)	7.38	Insider Own	2.39%	Shs Outstand	20.03M	Perf Week	4.40%
Market Cap	4.65B	Forward P/E	20.84	EPS next Y	11.13	Insider Trans	-8.29%	Shs Float	19.56M	Perf Month	3.16%
Enterprise Value	4.32B	PEG	1.26	EPS next Q	1.99	Inst Own	104.60%	Short Float	7.70%	Perf Quarter	16.97%
Income	153.56M	P/S	16.94	EPS this Y	11.41%	Inst Trans	0.71%	Short Ratio	6.55	Perf Half Y	13.97%
Sales	274.48M	P/B	4.66	EPS next Y	22.87%	ROA	12.60%	Short Interest	1.51M	Perf YTD	22.68%
Book/sh	49.79	P/C	5.96	EPS next 5Y	16.58%	ROE	17.13%	52W High	247.38 -6.23%	Perf Year	129.87%
Cash/sh	38.89	P/FCF	37.76	EPS past 3/5Y	- -	ROIC	10.60%	52W Low	98.89 134.56%	Perf 3Y	221.59%
Dividend Est.	-	EV/EBITDA	31.83	Sales past 3/5Y	10.96% 7.54%	Gross Margin	83.42%	Volatility	3.17% 4.08%	Perf 5Y	205.41%
Dividend TTM	-	EV/Sales	15.74	EPS Y/Y TTM	210.12%	Oper. Margin	36.88%	ATR (14)	8.89	Perf 10Y	192.71%
Dividend Ex-Date	Jul 02, 2010	Quick Ratio	20.95	Sales Y/Y TTM	51.24%	Profit Margin	55.95%	RSI (14)	57.37	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	21.28	EPS Q/Q	69.66%	SMA20	3.76%	Beta	1.21	Target Price	277.11
Payout	0.00%	Debt/Eq	0.45	Sales Q/Q	14.09%	SMA50	6.30%	Rel Volume	0.65	Prev Close	234.66
Employees	47	LT Debt/Eq	0.45	Earnings	May 07 BMO	SMA200	18.87%	Avg Volume	229.93K	Price	231.96
IPO	Nov 18, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.23% -11.88%	Trades		Volume	150,495	Change	-1.15%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-26	Initiated	BofA Securities	Buy	$244
Dec-09-25	Initiated	Citigroup	Buy	$270
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral

Show Previous Ratings

May-27-26 04:01PM	Ligand to Participate in June Investor Conferences (GlobeNewswire)
May-07-26 07:28AM	Ligand: Q1 Earnings Snapshot (Associated Press) -9.55%
07:00AM	Ligand Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-05-26 04:01PM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-27-26 10:19AM	Royalty Powerhouse: Ligand And Xoma Unite In $739 Million Deal (Investor's Business Daily)
09:10AM	Loading…
09:10AM	Ligand Pharmaceuticals buying Xoma Royalty for $739 million (Quartz)
07:00AM	Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator (GlobeNewswire)
06:00AM	Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million (The Wall Street Journal)
Apr-22-26 07:00AM	Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
Apr-14-26 07:00AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan) in FSGS (GlobeNewswire) +8.85%
Mar-26-26 07:00AM	Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team (GlobeNewswire)
Mar-12-26 04:25PM	How A Broad Sell-Off Rattled Top 3% Breakout Stock Ligand Pharma (Investor's Business Daily)
Mar-11-26 01:49PM	Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says (Proactive)
09:40AM	Oracle, Nike upgraded: Wall Street's top analyst calls (The Fly)
07:45AM	Here Are Wednesday's Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More (24/7 Wall St.)
06:11AM	Loading…
06:11AM	Ligand initiated with a Buy at BofA (TipRanks)
Mar-10-26 05:14PM	IBD Stock Of The Day: Ligand Pharma, Biotech's Royalty Arm, Breaks Out (Investor's Business Daily)
Mar-06-26 12:47PM	This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59% (Investor's Business Daily)
09:12AM	These Are The 5 Best Stocks To Buy Or Watch Now (Investor's Business Daily)
Mar-04-26 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire)
Feb-26-26 05:03PM	Ligand Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:10PM	Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Highlights: Surpassing Expectations and ... (GuruFocus.com)
07:50AM	Ligand: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-23-26 04:10PM	Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J (Investor's Business Daily)
08:44AM	Gilead Bets Big On Anito-Cel With $7.8 Billion Arcellx Deal (Investor's Business Daily)
Feb-12-26 07:00AM	Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-04-26 07:00AM	Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-13-26 04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily) -8.72%
10:32AM	Loading…
Jan-12-26 10:32AM	Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 (Barchart)
Jan-08-26 07:13AM	Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military' (Investor's Business Daily)
Jan-07-26 05:05PM	Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys (Investor's Business Daily)
Dec-09-25 07:00AM	Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance (GlobeNewswire)
Nov-20-25 01:34PM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year (Investor's Business Daily)
Nov-19-25 08:11AM	What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? (Insider Monkey)
Nov-18-25 08:03AM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year (Investor's Business Daily)
Nov-10-25 05:31AM	Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer (Pharmaceutical Technology)
Nov-06-25 07:14AM	Ligand: Q3 Earnings Snapshot (Associated Press Finance) +9.37%
07:00AM	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Oct-30-25 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
Oct-23-25 07:00AM	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	Ligand to Host Investor Day on December 9, 2025 (GlobeNewswire)
Oct-09-25 07:00AM	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients (GlobeNewswire)
Aug-19-25 04:00PM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-25 04:00PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Aug-12-25 08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-11-25 11:46PM	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (GlobeNewswire)
07:00AM	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (GlobeNewswire)
Aug-07-25 07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Jul-31-25 04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-24-25 07:00AM	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-17-25 02:10PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily) +6.13%
Jul-12-25 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire)
Aug-20-24 09:00AM	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-06-24 04:01PM	Ligand Reports Second Quarter 2024 Financial Results (Business Wire) -5.78%
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

MBATodd Christopher Davis

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Espinoza Octavio	Chief Financial Officer	May 27 '26	Option Exercise	57.58	1,736	99,966	27,679	May 28 07:43 PM
KOZARICH JOHN W	Director	May 13 '26	Option Exercise	69.51	1,575	109,478	43,361	May 14 09:08 PM
KOZARICH JOHN W	Director	May 12 '26	Option Exercise	69.51	459	31,905	42,245	May 14 09:08 PM
KOZARICH JOHN W	Director	May 13 '26	Sale	223.50	1,575	352,012	41,786	May 14 09:08 PM
KOZARICH JOHN W	Director	May 01 '26	Sale	231.80	467	108,251	41,786	May 14 09:08 PM
KOZARICH JOHN W	Director	May 12 '26	Sale	224.00	459	102,816	41,786	May 14 09:08 PM
JOHN KOZARICH	Director	May 13 '26	Proposed Sale	223.50	1,575	352,012		May 13 04:09 PM
JOHN KOZARICH	Director	May 12 '26	Proposed Sale	224.00	459	102,816		May 12 05:45 PM
Reardon Andrew	CLO & Secretary	May 01 '26	Option Exercise	52.27	5,000	261,350	46,382	May 04 08:20 PM
Reardon Andrew	CLO & Secretary	May 01 '26	Sale	231.31	5,000	1,156,556	41,382	May 04 08:20 PM
KOZARICH JOHN W	Director	May 01 '26	Proposed Sale	229.87	467	107,349		May 01 04:16 PM
KOZARICH JOHN W	Director	Apr 01 '26	Sale	202.23	467	94,440	42,253	Apr 02 07:43 PM
Reardon Andrew	CLO & Secretary	Apr 01 '26	Option Exercise	52.27	5,000	261,350	46,382	Apr 02 06:56 PM
Reardon Andrew	CLO & Secretary	Apr 01 '26	Sale	201.24	5,000	1,006,224	41,382	Apr 02 06:56 PM
KOZARICH JOHN W	Director	Apr 01 '26	Proposed Sale	203.50	467	95,034		Apr 01 04:10 PM
LAMATTINA JOHN L	Director	Mar 06 '26	Option Exercise	114.15	2,161	246,678	32,885	Mar 31 05:53 PM
LAMATTINA JOHN L	Director	Mar 06 '26	Sale	200.76	2,161	433,842	30,724	Mar 31 05:53 PM
Sabba Stephen L	Director	Mar 23 '26	Sale	207.87	1,000	207,873	32,793	Mar 25 11:13 AM
STEPHEN L. SABBA	Director	Mar 23 '26	Proposed Sale	207.87	1,000	207,873		Mar 23 04:04 PM
Espinoza Octavio	Chief Financial Officer	Mar 11 '26	Option Exercise	92.65	2,405	222,823	24,067	Mar 13 07:29 PM
Espinoza Octavio	Chief Financial Officer	Mar 11 '26	Sale	225.00	3,057	687,825	21,010	Mar 13 07:29 PM
OCTAVIO ESPINOZA	Officer	Mar 11 '26	Proposed Sale	212.29	3,057	648,971		Mar 11 04:42 PM
Reardon Andrew	CLO & Secretary	Mar 04 '26	Option Exercise	52.27	5,000	261,350	41,869	Mar 06 06:51 PM
Reardon Andrew	CLO & Secretary	Mar 04 '26	Sale	206.35	5,000	1,031,770	36,869	Mar 06 06:51 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '26	Option Exercise	63.49	2,073	131,609	35,085	Mar 06 06:49 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '26	Sale	205.83	13,423	2,762,822	21,662	Mar 06 06:49 PM
JOHN L LAMATTINA	Director	Mar 06 '26	Proposed Sale	200.76	2,161	433,842		Mar 06 04:17 PM
Sabba Stephen L	Director	Mar 03 '26	Option Exercise	69.51	2,034	141,383	35,827	Mar 05 11:05 AM
Sabba Stephen L	Director	Mar 03 '26	Sale	201.50	2,034	409,851	33,793	Mar 05 11:05 AM
KOZARICH JOHN W	Director	Mar 02 '26	Sale	200.50	467	93,632	42,720	Mar 04 09:04 PM
ANDREW REARDON	Officer	Mar 04 '26	Proposed Sale	204.24	20,000	4,084,800		Mar 04 04:44 PM
OCTAVIO ESPINOZA	Officer	Mar 04 '26	Proposed Sale	204.24	13,423	2,741,514		Mar 04 04:39 PM
STEPHEN L. SABBA	Director	Mar 03 '26	Proposed Sale	201.50	2,034	409,851		Mar 03 04:27 PM
KOZARICH JOHN W	Director	Feb 02 '26	Sale	195.91	467	91,490	43,187	Feb 04 05:18 PM
KOZARICH JOHN W	Director	Feb 02 '26	Proposed Sale	192.18	467	89,748		Feb 02 04:12 PM
KOZARICH JOHN W	Director	Jan 02 '26	Sale	189.58	467	88,532	43,654	Jan 06 07:47 PM
KOZARICH JOHN W	Director	Jan 02 '26	Proposed Sale	188.60	467	88,076		Jan 02 04:04 PM
Espinoza Octavio	Chief Financial Officer	Dec 16 '25	Option Exercise	69.00	2,381	164,298	28,567	Dec 18 04:19 PM
Espinoza Octavio	Chief Financial Officer	Dec 12 '25	Sale	188.31	1,804	339,711	26,186	Dec 16 06:36 PM
OCTAVIO ESPINOZA	Officer	Dec 12 '25	Proposed Sale	188.31	1,804	339,711		Dec 12 05:22 PM
Aryeh Jason	Director	Dec 08 '25	Option Exercise	69.51	2,034	141,383	71,323	Dec 08 07:38 PM
KOZARICH JOHN W	Director	Dec 01 '25	Sale	195.84	467	91,457	44,121	Dec 03 05:08 PM
KOZARICH JOHN W	Director	Dec 01 '25	Proposed Sale	199.88	467	93,344		Dec 01 04:08 PM
Gray Nancy Ryan	Director	Nov 07 '25	Option Exercise	69.58	6,571	457,185	11,650	Nov 12 04:45 PM
Gray Nancy Ryan	Director	Nov 07 '25	Sale	205.45	6,571	1,350,012	8,094	Nov 12 04:45 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Option Exercise	67.78	4,179	283,232	32,869	Nov 12 04:44 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Sale	205.45	4,179	858,576	30,724	Nov 12 04:44 PM
NANCY GRAY	Director	Nov 07 '25	Proposed Sale	205.45	6,571	1,350,012		Nov 07 05:05 PM
JOHN L LAMATTINA	Director	Nov 07 '25	Proposed Sale	205.45	4,179	858,576		Nov 07 04:05 PM
KOZARICH JOHN W	Director	Nov 03 '25	Sale	191.05	467	89,219	44,588	Nov 05 05:22 PM
KOZARICH JOHN W	Director	Nov 03 '25	Proposed Sale	191.05	467	89,219		Nov 03 04:05 PM
KOZARICH JOHN W	Director	Oct 01 '25	Sale	179.44	467	83,800	45,055	Oct 03 04:45 PM
KOZARICH JOHN W	Director	Oct 01 '25	Proposed Sale	176.68	467	82,510		Oct 01 04:09 PM
Aryeh Jason	Director	Sep 23 '25	Sale	170.81	10,000	1,708,088	69,289	Sep 24 05:11 PM
JASON M ARYEH	Director	Sep 23 '25	Proposed Sale	170.81	10,000	1,708,087		Sep 23 04:50 PM
Aryeh Jason	Director	Sep 17 '25	Proposed Sale	168.50	10,000	1,685,000		Sep 17 12:41 PM
KOZARICH JOHN W	Director	Sep 02 '25	Sale	162.26	467	75,775	45,522	Sep 04 05:47 PM
KOZARICH JOHN W	Director	Sep 02 '25	Proposed Sale	161.71	467	75,518		Sep 02 04:16 PM
KOZARICH JOHN W	Director	Aug 01 '25	Sale	131.88	467	61,586	45,989	Aug 05 05:03 PM
KOZARICH JOHN W	Director	Aug 01 '25	Proposed Sale	131.00	467	61,177		Aug 01 04:04 PM
KOZARICH JOHN W	Director	Jul 10 '25	Sale	125.00	934	116,750	46,456	Jul 11 06:17 PM
KOZARICH JOHN W	Officer	Jul 10 '25	Proposed Sale	125.00	934	116,750		Jul 10 05:08 PM
Reardon Andrew	CLO & Secretary	Jun 23 '25	Sale	114.08	500	57,042	31,903	Jun 24 08:29 PM
ANDREW THOMAS REARDON	Officer	Jun 23 '25	Proposed Sale	114.08	500	57,042		Jun 23 05:07 PM
Reardon Andrew	CLO & Secretary	Jun 10 '25	Sale	114.54	500	57,271	32,403	Jun 12 05:51 PM
ANDREW THOMAS REARDON	Officer	Jun 10 '25	Proposed Sale	114.54	500	57,271		Jun 10 06:49 PM

OBIO

Orchestra BioMed Holdings Inc

LGND

Ligand Pharmaceuticals Inc

Upgrade your Finviz experience